SYDNEY, March 3, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN'), an Australian-US drug discovery company focused on the clinical development of drugs targeting two novel drug targets pertinent to a range of therapeutic indications, announced today that Graham Kelly, PhD, CEO and Executive Chairman, will present at the AusBiotech "Broker Meets Biotech" event held Wednesday 4 March 2015 at 5.00pm (AEDT) in the offices of Deloitte, 225 George St, The Rocks, Sydney.
Novogen will be presenting alongside four other selected Biotech Companies to an audience of brokers and investors.
About AusBiotech Broker Meets Biotech
AusBiotech is Australia's industry organisation, working on behalf of members for more than 27 years to provide representation and services to promote the global growth of Australian biotechnology.
AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.
Broker Meets Biotech events are held periodically to give local investors the opportunity to hear in-depth presentations from a number of biotechnology companies. These events also provide an opportunity for investors to gain further insight into recent developments, highlights and future outlooks of the biotech sector as a whole.
For more information visit www.ausbiotech.org
About Novogen Limited
Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc., with Yale University.
Novogen has two Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on our websites www.novogen.com
For more information please contact:
| Corporate Contact Dr. Graham Kelly Executive Chairman & CEO Novogen Group +61 (0) 2 9472 4100 |
Media Enquiries Cristyn Humphreys Chief Operating Officer Novogen Group +61 (0) 2 9472 4111 |
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "appear," "intends," "hopes," "anticipates," "believes," "could," "should," "would," "may," "target," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company's two proprietary technology platforms, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
